±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 4635  |  »Ø¸´: 69
¡¾½±Àø¡¿ ±¾Ìû±»ÆÀ¼Û60´Î£¬×÷Õßzhuimengren639Ôö¼Ó½ð±Ò 56.5 ¸ö
µ±Ç°Ö÷ÌâÒѾ­´æµµ¡£
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

[×ÊÔ´] ·ÖÏí£ºµÂ¹úº£µÂ±¤´óѧHugo Kubinyi½ÌÊÚµÄÒ©ÎïÉè¼ÆµÄ¿Î¼þ

µÂ¹úUniversity of HeidelbergµÄÖøÃûÒ©Îﻯѧ¼ÒHugo Kubinyi¹ØÓÚÒ©ÎïÉè¼ÆµÄ¿Î¼þ£¬ÏàÐŶԸãÒ©ÎïÉè¼ÆµÄͬѧ»áÓÐÓõġ£

Èç¹û¸Ð¾õµ¥¸öÏÂÔØÌ«Âé·³£¬ÄÇô¿ÉÒÔÓà flashget/ѸÀ×ÅúÁ¿ÏÂÔØ£¬Ï£Íû´ó¼ÒÄܹ»Ï²»¶£¬Ó»Ô¾ÆÀÂÛ£¡

¿´µ½ÓÐÕâô¶à³æÓÑϲ»¶Õâ¸ö¿Î¼þ£¬ÎªÁ˸Ðл´ó¼Ò£¬ÎÒ°ÑÎÒÏÂÔØµÄ´«µ½ÄÉÃ×ÅÌÉϹ©´ó¼ÒÏÂÔØ£¬µØÖ·ÈçÏÂ
http://www.namipan.com/d/Hugo%20 ... c4504bad9361a9db300


ÄÚÈÝ:

Drug Discovery (758 kBlack Eye
http://www.kubinyi.de/dd-01.pdf

Serendipity and Rational Design (374 kBlack Eye
http://www.kubinyi.de/dd-02.pdf

Chemogenomics (1,453 kBlack Eye
http://www.kubinyi.de/dd-03.pdf

Ligand-Receptor Interactions (647 kBlack Eye
http://www.kubinyi.de/dd-04.pdf

Hydrogen Bonds and Biological Activities (359 kBlack Eye
http://www.kubinyi.de/dd-05.pdf

Chemical Similarity and Biological Activities (686 kBlack Eye
http://www.kubinyi.de/dd-06.pdf

Drug Metabolism (501 kBlack Eye
http://www.kubinyi.de/dd-07.pdf

Peptidomimetics and Prodrugs (294 kBlack Eye
http://www.kubinyi.de/dd-08.pdf

Combinatorial Chemistry Technology (147 kBlack Eye
http://www.kubinyi.de/dd-09.pdf

Combinatorial Chemistry in Drug Research (215 kBlack Eye
http://www.kubinyi.de/dd-10.pdf

QSAR Parameters (284 kBlack Eye
http://www.kubinyi.de/dd-11.pdf

QSAR - Hansch and Free Wilson Analyses (153 kBlack Eye
http://www.kubinyi.de/dd-12.pdf

Variable Selection and Model Validation (935 kBlack Eye
http://www.kubinyi.de/dd-13.pdf

Nonlinear QSAR and 3D QSAR (173 kBlack Eye
http://www.kubinyi.de/dd-14.pdf

QSAR Examples (138 kBlack Eye
http://www.kubinyi.de/dd-15.pdf

Structure-Based Ligand Design (782 kBlack Eye
http://www.kubinyi.de/dd-16.pdf

Computer-Aided Ligand Design (850 kBlack Eye
http://www.kubinyi.de/dd-17.pdf

Pharmacophore Analyses (486 kBlack Eye
http://www.kubinyi.de/dd-18.pdf

Virtual Screening (299 kBlack Eye
http://www.kubinyi.de/dd-19.pdf

Combinatorial and Fragment-Based Ligand Design (945 kBlack Eye
http://www.kubinyi.de/dd-20.pdf

Serine Proteases and their Inhibitors (371 kBlack Eye
http://www.kubinyi.de/dd-21.pdf

Thrombin Inhibitor Design (332 kBlack Eye
http://www.kubinyi.de/dd-22.pdf

Problems in Drug Design (1,043 kBlack Eye
http://www.kubinyi.de/dd-23.pdf

In Search for New Leads
http://www.kubinyi.de/paris-07-05.pdf

From Leads to Drugs
http://www.kubinyi.de/wien-06-05.pdf

Validation and Predictivity of QSAR Models
http://www.kubinyi.de/istanbul-2004-lecture.pdf

[ Last edited by zhuimengren639 on 2008-10-25 at 22:39 ]
»Ø¸´´ËÂ¥

» ÊÕ¼±¾ÌûµÄÌÔÌûר¼­ÍƼö

¸öÈËËѼ¯¾«»ª

» ²ÂÄãϲ»¶

» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

ÙÚ½¨²¨

³¬¼¶°æÖ÷

ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡


¡ï¡ï¡ï¡ï¡ï ÎåÐǼ¶,ÓÅÐãÍÆ¼ö

лл£¡£¡£¡£¡£¡£¡£¡£¡£¡£¡
21Â¥2008-10-25 21:52:32
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 70 ¸ö»Ø´ð

xufund

¹ÜÀíÔ±

ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡


¡ï¡ï¡ï¡ï¡ï ÎåÐǼ¶,ÓÅÐãÍÆ¼ö

very good
thanks
2Â¥2008-10-24 21:09:49
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

gp0713

ר¼Ò¹ËÎÊ

ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡


¡ï¡ï¡ï¡ï¡ï ÎåÐǼ¶,ÓÅÐãÍÆ¼ö

very good£¡thanks£¡
3Â¥2008-10-24 21:59:33
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

lijianyong

°æÖ÷

ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡ÓÅÐ㣡£¡ÓÐľÓУ¡£¡£¡


¡ï¡ï¡ï¡ï¡ï ÎåÐǼ¶,ÓÅÐãÍÆ¼ö

ºÃµÄºÜ°¡
лл
ÓйØÒ©ÎïÉè¼Æ¶¼»¶Ó­
5Â¥2008-10-25 03:15:15
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
¼òµ¥»Ø¸´
2008-10-24 22:03   »Ø¸´  
 
¡î ÎÞÐǼ¶ ¡ï Ò»ÐǼ¶ ¡ï¡ï¡ï ÈýÐǼ¶ ¡ï¡ï¡ï¡ï¡ï ÎåÐǼ¶
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] ÉúÎïѧ308·ÖÇóµ÷¼Á£¨Ò»Ö¾Ô¸»ª¶«Ê¦´ó£© +3 ÏàÐűػá¹ââÍòÕ 2026-03-31 3/150 2026-04-01 02:16 by СÇཷ26
[¿¼ÑÐ] 311Çóµ÷¼ÁÒ»Ö¾Ô¸ºÏ·Ê¹¤Òµ´óѧ +11 Çï¶þÊ®¶þ 2026-03-30 11/550 2026-03-31 18:09 by 253863592
[¿¼ÑÐ] 085601Ó¢¶þÊý¶þÇóµ÷¼Á ×Ü·Ö325 +4 Óຽº½ 2026-03-31 4/200 2026-03-31 17:38 by ÌÆãå¶ù
[¿¼ÑÐ] 318Çóµ÷¼Á +10 ³Â³¿79 2026-03-30 10/500 2026-03-31 17:37 by 544594351
[¿¼ÑÐ] ½­ËÕËÕ±±¸ßУ³ÏÑûµ÷¼Áͬѧ +3 zzll406 2026-03-31 3/150 2026-03-31 16:54 by ¼°Ê±ÐÐÀÖfan
[¿¼ÑÐ] ¿¼Ñе÷¼ÁÇóÖú +7 13287130938 2026-03-31 7/350 2026-03-31 16:39 by 690616278
[¿¼ÑÐ] 354Çóµ÷¼Á +3 lxb598 2026-03-31 4/200 2026-03-31 13:42 by sophie2180
[¿¼ÑÐ] 287Çóµ÷¼Á +17 land xuxu 2026-03-26 17/850 2026-03-31 11:16 by Zzxxxs
[¿¼ÑÐ] 332Çóµ÷¼Á +6 Lyy930824@ 2026-03-29 6/300 2026-03-30 10:53 by 1172367218
[¿¼ÑÐ] 348Çóµ÷¼Á +6 СÀÁ³æ²»ÀÁÁË 2026-03-28 6/300 2026-03-30 10:29 by Evan_Liu
[¿¼ÑÐ] Ò»Ö¾Ô¸±±¾©¹¤Òµ´óѧ£¬324·ÖÇóµ÷¼Á +6 Áã°Ë# 2026-03-28 6/300 2026-03-29 21:20 by nanaliuyun
[¿¼ÑÐ] 343Çóµ÷¼Á085601 +3 ҪŬÁ¦Ñ§Ï°x 2026-03-29 3/150 2026-03-29 18:35 by wxiongid
[¿¼ÑÐ] 321Çóµ÷¼Á +7 è±Óñ~~ 2026-03-25 8/400 2026-03-29 06:41 by 544594351
[¿¼ÑÐ] ÊýÒ»Ó¢Ò»271ר˶£¨085401£©Çóµ÷¼Á£¬¿É¿ç +7 ǰÐбØÓйâ 2026-03-28 8/400 2026-03-28 23:22 by Сľ³ætim
[¿¼ÑÐ] 071000ÉúÎïѧÇóµ÷¼Á£¬³õÊԳɼ¨343 +7 ССÌðÃæÍÅ 2026-03-25 7/350 2026-03-28 20:25 by ÌÆãå¶ù
[¿¼ÑÐ] Ò»Ö¾Ô¸»ªÀí£¬ÊýÒ»Ó¢Ò»285ÇóAÇøµ÷¼Á +8 AZMK 2026-03-25 12/600 2026-03-28 18:15 by AZMK
[Óлú½»Á÷] ¸ßθßѹ·´Ó¦ÇóÖú 10+4 chibby 2026-03-25 4/200 2026-03-27 21:08 by BT20230424
[¿¼ÑÐ] 08¿ªÍ·275Çóµ÷¼Á +4 À­Ë­²»ÖØÒª 2026-03-26 4/200 2026-03-27 14:12 by Delta2012
[¿¼ÑÐ] ¿¼Ñе÷¼Á +9 СÀ¯ÐÂ±Ê 2026-03-26 9/450 2026-03-27 11:10 by ²»³Ôô~µÄ؈
[¿¼ÑÐ] Ò»Ö¾Ô¸¼ª´ó071010£¬316·ÖÇóµ÷¼Á +3 xgbiknn 2026-03-27 3/150 2026-03-27 10:36 by guoweigw
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û